期刊文献+

HPLC法测定利伐沙班原料药的有关物质

Determination of Related Substances in Rivaroxaban by HPLC
下载PDF
导出
摘要 目的:建立测定利伐沙班原料药的有关物质的HPLC方法。方法:采用Waters XBridge RP18(250*4.6 mm,5μm)色谱柱,采用梯度洗脱方式进行洗脱;0.1 mol/L的磷酸二氢钠-乙腈(95∶5)为流动相A,乙腈为流动相B,检测波长240 nm,柱温30℃,流速1.0 mL/min。结果:利伐沙班及其已知杂质(杂质A、杂质B、杂质C、杂质D、杂质E、杂质F)在浓度0.15~3.0μg/m L范围内线性关系良好。平均回收率分别为94.7%、95.8%、100.6%、96.4%、96.9%。结论:该方法专属性强、灵敏度高、操作简便,适用于利伐沙班原料药有关物质的测定。 Objective: To establish a HPLC method for determination of rivaroxaban related substances. Methods:The analysis was performed on a Waters XBridge RP 18 (250x4.6 mm, 5μm). The mobile phase was composed of Acetonitrile and 0. IM phosphate buffer solution with the volume ratio of 5 : 95. The flow rate of mobile phase and the detection wavelength and the column temperature were 1.0 mL/min and 240 nm and 30 ℃, respectively. Results: The chromatographic peak area and concentration Hydrochlorothiazide showed a good linear relationship at the range of 0.15-3.0 μg/mL. The average recovery of Hydrochlorothiazide was 94.7 %, 95.8 %, 100.6 %, 96.4%, 96.9 %. Conclusion:The method is specific, sensitive and simple operation. It can be used for determination of rivaroxaban related substances.
出处 《广东化工》 CAS 2017年第24期94-95,共2页 Guangdong Chemical Industry
关键词 利伐沙班原料药 有关物质 HPLC Rivaroxaban related substances: HPLC
  • 相关文献

参考文献2

二级参考文献21

  • 1Friedman RJ,Dahl OE,Rosencher N,et al.Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty:a pooled analysis of three trials[J].Thromb Res,2010,126(3):175-182.
  • 2Eriksson BI,Dahl OE,Huo MH,et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*)[J].Thromb Haemost,2011,105(4):721-729.
  • 3Schulman S,Kearon C,Kakkar AK,et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J].N Engl J Med,2009,361(24):2342-2352.
  • 4Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
  • 5Wann LS,Curtis AB,Ellenbogen KA,et al.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran):a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2011,123(10):1144-1150.
  • 6Oldgren J,Budaj A,Granger CB,et al.Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double-blind,phase II trial[J].Eur Heart J,2011,32(22):2781-2789.
  • 7Eriksson BI,Borris LC,Friedman RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-2775.
  • 8Kakkar AK,Brenner B,Dahl OE,et al.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind,randomised controlled trial[J].Lancet,2008,372(9632):31-39.
  • 9Lassen MR,Ageno W,Borris LC,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med,2008,358(26):2776-2786.
  • 10Turpie AG,Lassen MR,Davidson BL,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4):a randomised trial[J].Lancet,2009,373(9676):1673-1680.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部